ReShape Medical

ReShape Medical is commercializing a non-surgical weight-loss device and counselling program. The CE-Marked and FDA-approved ReShape Dual is an intra-gastric, dual-balloon system that aims to help the roughly 60 million Americans with a body mass index (BMI) between 30 and 40 achieve their weight-loss goals. ReShape addresses the need for the temporary and minimally invasive treatment of obesity. The device is implanted in the stomach via a simple endoscopic procedure, filled with a saline solution, and removed after six months. Patients undergoing the procedure also receive one year of nutritional counselling. ReShape Medical is positioned to be a new entrant in the large, untapped US market for non-surgical weight loss devices, estimated at more than USD 1 billion.

Recent News

August 26, 2015
ReShape Medical, Inc. Completes $38 Million Series D Financing Round Led by HealthCor Partners Management, L.P. and Endeavour Vision SA to Support U.S. Commercialization of ReShape™ Integrated Dual Balloon System Following Recent Approval by the FDA.


Company Info
Country: USA
Industry:    Medtech
Sector: medical technology
Status: Unrealized
Vehicle: Endeavour Medtech Growth LP

Key persons
 Rick Thompson, CEO

Company website

Endeavour Vision Team
Eric Milledge
Daniel Bertholet
© Endeavour Vision SA 2006-2017 Terms & Conditions